Funny, I thought the same thing. I almost bought before the close. Glad I didn't.
Boy, you don;t know anything about momentum stocks. Those may be sound reasons, but they have nothing to do with the price of YELP now. This has a relatively low float and is easily influenced by 1 or 2 traders. YELP will go down when they are done.
Having said that, I did short at $32.
Their forecast for next qtr and next year was in line at best. This has nothing to do with HomeAway being a good or bad business. It is just not priced right. Foward PE is 42. If you take that to a reasonable number of 20-21, that puts the PPS at $16-17. Forecasted revenue and earnings do not appear to exceed expectations.
Buy in AH if you think this is going up. But heed my warning. PPS is only going one direction in the near future...down.
Bingo, no great sell-off.....no surge to 100 either. It has been between 82 -85 all morning. No short term trade here,unless you are picking up nickels and dimes.
It always amazes me when there is big news on a stock...it jumps or plunges pre-market....and then remains in a narrow trading range all day. I predict this trades between 82-87 all day. Which is pretty narrow given the surge now.
Crazy...that is all I can say. Not sure where this will end up. Especially since making money this new drug is still 1-3 years out. Crazy
Will CRUS have to go down to $16 to find support? Or is it trying to establish a bottom in the 18.30 area? It seems that the 2 year support around $16 is a bit of a stretch. Especially since today's drop is already extreme.
And, some investors took CRUS off pre-market lows of $19 all the way back to $20. I think there is investor support to start buying near current levels. But ya never know.
I won't argue its potential. But the PPS appears priced for perfection. I still feel this needs a 10-15% correction. As I speak some of the air is being let out of the balloon,
You are right, market this morning does like it more than I . Nice pop on low volume. I still think that PSMT is about 10-15% over valued. JMHO
You can't look at one (EPS) without looking at the other (Revenue). If you want to say that EPS beat analyst expectations, then you have to acknowledge that revenue missed. And unless they provide better revenue guidance, future EPS beats will be difficult.
In the short term, it looks like short covering will buoy PSFT. At least AH.
Well, its like squeezing blood from a rock. Revenue growth needs to accelerate, otherwise it will be tougher and tougher to pinch pennies in order to increase EPS.